[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ischemic-stroke-acute\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ischemic-stroke-acute":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,37,0,25,[9,48,75,106,136,162,186,214,234,260,280,307,328,360,386,409,430,456,482,506,534,559,584,612,635],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100643898","phase-3-intra-arterial-thrombolysis-for-acute-ischemic-stroke-with-medium-vessel-occlusion-100643898",false,"NCT07668323","Intra-arterial Thrombolysis For Acute Ischemic Stroke With Medium Vessel Occlusion","Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion： A Multicenter Prospective Randomized Controlled Clinical Trial","IAT-MEVO","Inclusion Criteria:\n\n* Age 18 to 80 years.\n* Time from symptom onset or last known well to randomization within 24 hours.\n* Clinical diagnosis of acute ischemic stroke confirmed by CTA or MRA as being caused by isolated acute medium vessel occlusion, including distal M2\u002FM3 segments of the middle cerebral artery, A2\u002FA3 segments of the anterior cerebral artery, or P1\u002FP2\u002FP3 segments of the posterior cerebral artery. Isolated occlusion is defined as a single symptomatic vessel occlusion; patients with multiple vessel occlusions or uncertain culprit vessel are excluded.\n* Baseline NIHSS score ≥ 6, or 3-5 with disabling deficits (e.g., motor weakness, aphasia, visual field defects), and NIHSS score ≤ 25 at the time of randomization.\n* For patients presenting beyond 6 hours from symptom onset: perfusion imaging criteria require Tmax \\> 6s volume ≥ 10 cc, and core infarct volume (defined as rCBF \\\u003C 30%) less than 50% of the Tmax \\> 6s volume.\n* Patient or legally authorized representative is able to understand and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* Clinical Exclusion Criteria:\n* Pre-stroke modified Rankin Scale (mRS) score \\> 2.\n* Presence of contraindications to intravenous thrombolysis.\n* Known allergy to heparin, contrast media, anesthetics, or other definite contraindications to endovascular treatment.\n* Comorbid severe diseases that may affect outcome assessment, including but not limited to malignancy, severe heart failure, or renal failure, with expected life expectancy \\\u003C 6 months.\n* Uncontrolled hypertension refractory to medical therapy (systolic blood pressure \\> 220 mmHg or diastolic blood pressure \\> 120 mmHg).\n* Baseline blood glucose \\\u003C 2.8 mmol\u002FL (50 mg\u002FdL) or \\> 22.2 mmol\u002FL (400 mg\u002FdL).\n* Known bleeding diathesis, including but not limited to: platelet count \\\u003C 100 × 10⁹\u002FL; heparin treatment within 48 hours with APTT ≥ 35 seconds; oral warfarin with INR \\> 3. Note: Patients without a history or suspicion of coagulation disorders do not require laboratory testing for coagulation parameters prior to enrollment.\n* Stroke onset with seizure or seizure occurring during the course of stroke, precluding accurate determination of baseline NIHSS score.\n* Female patients who are pregnant, lactating, or have a positive pregnancy test at hospital admission.\n* Currently participating in another investigational drug or device study that may interfere with the results of this study.\n* Other conditions judged by the investigator to be unsuitable for participation or posing significant risk to the patient.\n* Imaging Exclusion Criteria:\n* Intracranial hemorrhage confirmed by baseline head CT or MRI, including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, or subdural\u002Fepidural hemorrhage.\n* Presence of midline shift or cerebral herniation, or other ventricular mass effect with midline shift.\n* Anticipated inability to complete endovascular treatment due to vascular tortuosity, severe vessel wall calcification, or other anatomical challenges.\n* Aortic dissection.\n* Multiple vessel occlusions confirmed by CTA or MRA with inability to identify the symptomatic culprit vessel, such as bilateral middle cerebral artery occlusion or concurrent middle cerebral artery and basilar artery occlusion.\n* Suspected or confirmed non-acute occlusion of the symptomatic culprit vessel.","ALL","18 Years","80 Years",{"count":22,"type":23},306,"ESTIMATED","INTERVENTIONAL",[26],"PHASE3","Study purpose:\n\nA multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) phase III trial is planned to evaluate the efficacy and safety of intra-arterial thrombolysis (IAT) in patients with acute ischemic stroke caused by medium vessel occlusion (MeVO), compared with best medical management alone.\n\nEligible participants (aged 18-80 years, baseline NIHSS score 6-25 or 3-5 with disabling deficits, confirmed MeVO within 24 hours of symptom onset) will be randomly assigned 1:1 to the intra-arterial thrombolysis plus best medical management group or the best medical management alone group.\n\nPrimary endpoint: proportion of patients with favorable functional outcome (modified Rankin Scale score 0-2) at 90±7 days post-randomization.\n\nSecondary endpoints:\n\n1. Recanalization rate (meTICI ≥ 2b) at 24±12 hours post-randomization;\n2. Early neurological improvement (NIHSS score change from baseline) at 7±1 days or discharge;\n3. Overall distribution of mRS scores at 90±7 days (shift analysis);\n4. Excellent functional outcome (mRS score 0-1) at 90±7 days;\n5. Health-related quality of life (EQ-5D-5L) at 90±7 days;\n6. Functional independence (Barthel Index score 95-100) at 90±7 days;\n7. Symptomatic intracranial hemorrhage (sICH) per Heidelberg criteria within 48 hours;\n8. Early neurological deterioration (NIHSS increase ≥ 4 points or any single item increase ≥ 2 points) within 7 days;\n9. Any intracranial hemorrhage within 48 hours;\n10. Procedure-related complications;\n11. All-cause mortality within 90±7 days.",[29,30],"Medium Vessel Occlusion","Ischemic Stroke, Acute",[32,33,34],"medium vessel occlusion","acute ischemic stroke","intra-arterial thrombolysis","NOT_YET_RECRUITING","2026-06-22",{"date":38,"type":39},"2026-06-25","ACTUAL",{"date":41,"type":23},"2026-07-01",{"date":43,"type":23},"2029-08-31",{"name":45,"class":46},"The First Affiliated Hospital with Nanjing Medical University","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":24,"phases":58,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100617916","phase-3-single-bolus-non-immunogenic-staphylokinase-in-patients-with-acute-ischemic-stroke-within-45-24-hours-of-symptom-onset-100617916","NCT07324837","Single Bolus Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset","A Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Efficacy and Safety of the Recombinant Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset (FRIDA-CT)","FRIDA-CT","Inclusion Criteria:\n\n1. Men and women aged 18 years and over;\n2. Acute ischemic stroke symptom onset between 4.5 to 24 hours prior to enrolment, including wake-up stroke and unwitnessed stroke, onset time refers to \"last-seen normal time\";\n3. Pre-stroke modified Rankin scale (mRS) score≤1;\n4. Internal carotid artery, middle cerebral artery M1 or M2 occlusion confirmed by CT\u002FMRI, internal carotid artery, middle cerebral artery M1 or M2 being responsible for signs and symptoms of acute ischemic stroke;\n5. Neuroimaging: target mismatch profile on CT or MRI perfusion: ischemic core volume \\\u003C70 mL, mismatch ratio≥1.8 and mismatch volume≥15 mL;\n6. Alberta Stroke Program Early CT score (ASPECTS) \\> 6;\n7. Baseline National Institutes of Health Stroke Scale (NIHSS) 6-25 (inclusive);\n8. The patient is not planned or cannot undergo thrombectomy or intravenous thrombolysis in accordance with the current version of the Clinical Guidelines;\n9. Written informed consent from patients or their legally authorized representatives.\n\nExclusion Criteria:\n\n1. Acute ischemic stroke within 4,5 h after symptom onset;\n2. Intended to proceed to endovascular treatment;\n3. Known hypersensitivity to the non-immunogenic staphylokinase;\n4. Convulsive seizures at the onset of the disease, if there is no certainty that the seizure is a clinical manifestation of acute ischemic stroke;\n5. Persistent blood pressure elevation (systolic ≥185 mmHg or diastolic ≥110 mmHg), and the inability to reduce systolic blood pressure below 180 mmHg or diastolic blood pressure below 105 mmHg;\n6. Blood glucose \\\u003C2.8 or \\>22.2 mmol\u002FL (after blood glucose level correction to the specified values, inclusion of the patient in the study is possible);\n7. Neuroimaging (CT, MRI) signs of intracranial hemorrhage, brain tumor, arteriovenous malformation, brain abscess, cerebral aneurysm;\n8. Subarachnoid hemorrhage;\n9. Major bleeding currently or within the past 6 months;\n10. Surgery on the brain or spinal cord in the last 2 months;\n11. Punctures of non-compressible arteries and veins in the last 7 days;\n12. Gastrointestinal or genitourinary bleeding in the last 3 weeks. Confirmed exacerbations of gastric ulcer and duodenal ulcer in the last 3 months;\n13. Platelet count below 100,000\u002Fmm3;\n14. Previous stroke or severe traumatic brain injury within 3 months;\n15. Unable to perform CT or MRI;\n16. History of hemorrhagic stroke or stroke of unspecified genesis;\n17. Multiple arterial occlusion (bilateral MCA occlusion, MCA occlusion accompanied with basilar occlusion);\n18. Concomitant use of indirect oral anticoagulants (warfarin) with INR \\> 1.7;\n19. Taking direct anticoagulants (heparin, heparinoids) in the previous 48 hours with an APTT value above normal;\n20. Taking new oral anticoagulants in the previous 48 hours with a thrombin time value above normal and the impossibility of administering the specific antagonist idarucizumab (for dabigatran) or the presence of anti-Xa activity (for rivaroxaban, apixaban and edoxaban).\n21. Severe liver disease, including liver failure, liver cirrhosis, portal hypertension (with esophageal varices), active hepatitis;\n22. Acute pancreatitis;\n23. Bacterial endocarditis, pericarditis;\n24. Arterial aneurysms, malformations of arteries and veins. Suspected dissecting aortic aneurysm;\n25. Cancer with an increased risk of bleeding;\n26. Major surgeries or severe injuries within the last 14 days, minor surgeries or invasive procedures within the last 10 days;\n27. Prolonged or traumatic cardiopulmonary resuscitation (more than 2 minutes);\n28. Hemorrhagic diathesis, including renal and hepatic failure;\n29. Data on bleeding or acute trauma (fracture) at the time of examination;\n30. Pregnant women, nursing mothers, or reluctant to use effective contraceptive measures during the period of trial.",{"count":57,"type":23},990,[26],"Multicenter, double-blind, randomized, placebo-controlled phase III clinical trial. At the clinical sites, patients with acute ischemic stroke within 4.5-24 hours of symptom onset will be randomized to receive a single bolus injection of the recombinant non-immunogenic staphylokinase (Fortelyzin®, LLC \"SuperGene\", Russia) or placebo.",[30],[62],"Ischemic Stroke","RECRUITING","2026-06-10",{"date":66,"type":39},"2026-06-12",{"date":68,"type":39},"2026-06-09",{"date":70,"type":23},"2029-01-01",{"name":72,"class":73},"Supergene, LLC","INDUSTRY",15,{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":24,"phases":85,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100523345","hospital-implementation-of-a-stroke-protocol-for-emergency-evaluation-and-disposition-100523345","NCT06094478","Hospital Implementation of a Stroke Protocol for Emergency Evaluation and Disposition","Implementation of a Stroke Protocol for Emergency Evaluation and Disposition","HI-SPEED","Inclusion Criteria:\n\n* Age \\>=18 years\n* Final diagnosis: AIS, ICH, or SAH\n\nExclusion Criteria:\n\n* Final diagnosis: TIA or stroke NOS\n* Age \\\u003C18 years\n* Comfort care measures on day 0 or 1\n* Left hospital against medical advice\n* Enrolled in clinical trial related to stroke that is competing with this study",{"count":84,"type":23},900,[86],"NA","Most stroke patients are initially evaluated at the closest hospital but some need to be transferred to a hospital that can provide more advanced care. The \"Door-In-Door-Out\" (DIDO) process at the first hospital can take time making transferred patients no longer able to get the advanced treatments. This study will help hospitals across the US \"stand up\" new ways to evaluate stroke patients, decide who needs to be transferred, and transfer them quickly for advanced treatment.",[89,30,90],"Stroke, Acute","Hemorrhagic Stroke",[92,93,94,95],"interhospital transfer","quality improvement","implementation science","stroke systems of care","2026-05-18",{"date":98,"type":39},"2026-05-20",{"date":100,"type":39},"2024-10-17",{"date":102,"type":23},"2028-07-31",{"name":104,"class":46},"University of Chicago",8,{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":24,"phases":115,"briefSummary":117,"conditions":118,"keywords":122,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":135},"100507832","phase-2-post-thrombectomy-intra-arterial-tenecteplase-for-acute-management-of-non-retrievable-thrombus-and-no-reflow-in-emergent-stroke-100507832","NCT05892510","Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke","Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke (EXTEND-AGNES TNK)","Inclusion Criteria:\n\n* Adult participants (age≥18 years) presenting with ischemic stroke with arterial LVO on CT\u002FMR Angiogram of the intracranial internal carotid or middle cerebral artery (MCA) first segment (M1) or proximal second segment (M2) committed to thrombectomy using standard criteria within 24 hours of onset:\n* For 0-6 hours of symptom onset: Presence of arterial occlusion as defined above and ASPECTS≥3 on NCCT\n* For 6-24 hours of symptom onset: Additional imaging criteria on CTP or MRI perfusion of core volume \\\u003C100ml.\n* Qualifying CT\u002FMR within 4hrs of randomisation (repeat CT for transferred participants required if \\>4hr)\n* Pre-stroke Modified Rankin Scale (mRS) score of ≤2 (mild pre-existing disability permitted)\n* Local legal requirements for consent have been satisfied.\n\nExclusion Criteria:\n\n* Intracranial hemorrhage identified by CT or MRI\n* ASPECTS 0-2 on NCCT\n* CTP or MRI perfusion ischemic core volume \\>100ml if presenting within 6-24 hours from symptoms onset\n* Anticipated endovascular stenting required for intracranial or extracranial atherosclerotic stenosis\u002Focclusion.\n* More than six retrieval attempts in the same vessel\n* Alteplase being infused within 30 minutes (\\~5x half-life) of anticipated trial drug administration\n* Contraindication to imaging with contrast agents\n* Any condition (eg.mid-arterial phase early venous filling) that in the judgment of investigators could impose hazards if study therapy is initiated\n* Pregnant women.\n* Current participation in another intervention research study that includes experimental interventions beyond standard-of-care.\n* Anticoagulation. INR ≤1.7 if on warfarin, and dabigatran reversal by idarucizumab are permitted.\n* Other standard contraindications to thrombolysis apart from time window.\n* Known terminal illness such that the participants would not be expected to survive a year.\n* Planned withdrawal of care or comfort care measures.",{"count":114,"type":23},462,[116,26],"PHASE2","Multicentre, prospective, Multi-arm Multi-stage (MAMS) seamless phase 2b\u002F3 interventional randomized placebo-controlled double-blinded parallel-assignment (2 arms with 1:1 randomization) efficacy and safety trial to test intra-arterial tenecteplase at the completion of thrombectomy versus best practice in participants with anterior circulation LVO receiving mechanical thrombectomy within 24 hours of symptoms onset.",[30,119,120,121],"Cerebrovascular Disorders","Brain Disorder","Central Nervous System Diseases",[123,124,125,126],"Tenecteplase","Fibrinolytic agents","Thrombectomy","No-reflow","2026-05-14",{"date":96,"type":39},{"date":130,"type":39},"2024-06-01",{"date":132,"type":23},"2027-11-30",{"name":134,"class":46},"University of Melbourne",12,{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":24,"phases":145,"briefSummary":146,"conditions":147,"keywords":148,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":161},"100485384","brain-oscillation-synchronized-stimulation-to-enhance-motor-recovery-in-early-subacute-stroke-100485384","NCT05600374","Brain-Oscillation-Synchronized Stimulation to Enhance Motor Recovery in Early Subacute Stroke","Boss-Stroke","Inclusion Criteria:\n\nSubjects meeting all of the following criteria will be considered for admission to the trial:\n\n1. Age ≥ 18 years at the time of signing the informed consent.\n2. Cerebral ischemia identified by brain imaging (cerebral MRI or CT) occurred 1-14 days ago.\n3. Subject understands and voluntarily signs an informed consent document prior to any study related assessments\u002Fprocedures.\n4. Stroke has resulted in a new arm-\u002Fhand motor deficit with ≤ 50 points in the FMA-UE.\n5. Presence of motor evoked potentials (MEPs) in the paretic hand. MEPs has to be obtained in the resting muscle\n\n   o If no MEPs can be obtained, MEP search procedure can be repeated later up to 14 days after stroke onset.\n6. ● μ-oscillation (8-12 Hz) is recordable by EEG in the ipsilesional sensorimotor cortex with a sufficient signal-to-noise ratio of at least 3 dB\n7. ● Subject is able to adhere to the study visit schedule and other protocol requirements.\n\nExclusion Criteria:\n\nSubjects presenting with any of the following criteria will not be included in the trial:\n\n1. Hemorrhagic stroke (this refers to primary intracerebral hemorrhage only; hemorrhagic transformation of ischemic infarcts is not an exclusion criterion)\n2. Estimated life expectancy \\\u003C 12 months\n3. Presence of intracranial ferromagnetic metal (extracranial stents ≥10 cm away from the TMS coil are acceptable) in accordance with current safety guidelines \\[18\\]\n4. Intraocular metal, cochlear implants\n5. If TMS might interact with sensors of active implants (e.g., intra-cardiac defibrillators).\n6. If a cranial bone gap affects currents induced by TMS (such as after craniotomy).\n7. History of seizures or epilepsy.\n8. Treatment intervention can't be started within 14 days after onset of stroke.\n9. Women during pregnancy and lactation.\n10. Participation in other studies if they are MDR or AMG studies or there is otherwise a high risk of insurance law issues intervening between two studies. In case of uncertainty, competing insurances must be contacted prior to participation\n11. persistent addiction disorder (except for nicotine dependence)\n12. CNS malignoma\n13. If there is any concern by the investigator regarding the safe participation of the subject in the study or for any other reason the investigator considers the subject inappropriate for participation in the study.\n14. The ability to consent for patients who are unable to speak will be assessed on the basis of the NIHS-Score by an independent physician (details see chapter 21 and appendix).",{"count":144,"type":23},144,[86],"We will investigate the therapeutic efficacy of EEG-synchronized noninvasive repetitive transcranial magnetic stimulation (rTMS) in the early subacute phase after ischemic stroke to improve upper limb motor rehabilitation. We hypothesize that synchronization of rTMS with the phase of the ongoing sensorimotor oscillation indicating high corticospinal excitability leads to significantly stronger improvement of paretic upper limb motor function than the same rTMS protocol non-synchronized to the ongoing sensorimotor oscillation or sham stimulation.",[30],[149,150,151,152],"Oscillation","motor recovery","Transcranial magnetic stimulation","EEG-synchronized",{"date":154,"type":39},"2026-05-15",{"date":156,"type":39},"2023-02-06",{"date":158,"type":23},"2028-02-28",{"name":160,"class":46},"University Hospital Tuebingen",4,{"id":163,"slug":164,"hasResults":12,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":169,"targetDuration":4,"studyType":24,"phases":171,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":47},"100622641","a-trial-of-adacolumn-on-cerebral-edema-after-anterior-circulation-ischemic-stroke-100622641","NCT07386262","A Trial of Adacolumn on Cerebral Edema After Anterior Circulation Ischemic Stroke","Efficacy and Safety of the Adacolumn® Granulocyte and Monocyte\u002FMacrophage Apheresis Device for Cerebral Edema After Acute Anterior Circulation Occlusive Cerebral Infarction: A Prospective, Randomized, Controlled Clinical Trial","Inclusion Criteria:\n\n1. Age 18-80 years, regardless of gender;\n2. A clinical diagnosis of acute ischemic stroke;\n3. Proven large vessel occlusion in ICA or MCA-M1 occlusion (carotid occlusions can be cervical or intracranial, with or without tandem MCA lesions) determined by MRA or CTA or DSA;\n4. NIHSS score ≥10 at screening;\n5. Pre-stroke mRS score \\\u003C2 (independent in all activities of daily living);\n6. Time from stroke onset to initiation of the first Adacolumn treatment is ≤24 hours, stroke onset is defined as the last time the patient was known to be at their neurological baseline (wake-up strokes qualify if within this time window);\n7. All endovascular thrombectomy procedures must strictly adhere to the \"2024 Chinese Stroke Association Guidelines for Reperfusion Therapy in Acute Ischemic Stroke\" and the latest prescribing information\u002Finstructions for use regarding indications, contraindications, and procedural standards;\n8. Written informed consent obtained from the patient or legally authorized representative.\n\nExclusion Criteria:\n\n1. Decompressive craniectomy performed before enrollment or between enrollment and initiation of study treatment;\n2. Patients who receive intravenous thrombolysis (including bridging therapy) for the index ischemic stroke episode before or during endovascular thrombectomy; or undergo permanent intracranial or extracranial stent implantation (including intracranial stent-assisted thrombectomy or carotid stenting) during the index endovascular procedure;\n3. After endovascular thrombectomy: extensive contrast extravasation (diffuse subarachnoid high density or parenchymal high density not consistent with hematoma), new subarachnoid hemorrhage（SAH）, or symptomatic intracranial hemorrhage (sICH);\n4. Large-vessel occlusion is attributed to other determined etiologies per TOAST classification, such as tumor-related, dissection-related, or other clearly identifiable non-LAA\u002Fnon-CE causes.\n5. Clinical signs of brain herniation, such as unilateral or bilateral fixed dilated pupils and\u002For other loss of brainstem reflexes attributable to cerebral edema or herniation in the investigator's opinion;\n6. Intracranial lesions conferring markedly increased bleeding risk (known brain tumor, arteriovenous malformation, aneurysm);\n7. Inability to undergo MRI;\n8. Absolute neutrophil count \\\u003C1.5×10⁹\u002FL or \\>15×10⁹\u002FL\n9. Absolute monocyte count \\> 1.0 ×10⁹\u002FL;\n10. Red blood cells \\\u003C3.0×10¹²\u002FL ;\n11. Active internal bleeding or bleeding tendency (such as platelet count \\\u003C100×10⁹\u002FL, INR \\>1.7, PT \\>15 seconds);\n12. Marked hypercoagulability (fibrinogen \\>700 mg\u002FdL);\n13. Intracranial or spinal surgery or severe head trauma within the past 3 months;\n14. Refractory hypertension (persistent systolic blood pressure \\>185 mmHg or diastolic \\>110 mmHg);\n15. Known allergy to components of the blood purification system (including adsorption membrane, anticoagulants);\n16. Acute ST-segment elevation myocardial infarction and\u002For acute decompensated heart failure and\u002For corrected QT interval \\>520 ms and\u002For history of cardiac arrest within the past 6 months(pulseless electrical activity, ventricular tachycardia, ventricular fibrillation, or asystole);\n17. Body temperature \\>38°C or active infection;\n18. Active autoimmune disease or immunodeficiency;\n19. Participation in another interventional clinical trial within the past 30 days;\n20. Any other condition deemed unsuitable for participation by the investigator.",{"count":170,"type":23},10,[86],"The primary objective is to investigate whether treatment with Adacolumn can ameliorate the progression of cerebral edema within 72 hours in patients with anterior circulation ischemic stroke. The secondary objective is to explore if Adacolumn could improve acute neurologic status, functional outcomes, treatment requirements and safety in patients with anterior circulation ischemic stroke.",[174,30,175,176],"Cerebral Edema","Malignant Cerebral Edema","Anterior Circulation Brain Infarction","2026-05-03",{"date":179,"type":39},"2026-05-05",{"date":181,"type":23},"2026-05-01",{"date":183,"type":23},"2028-12-31",{"name":185,"class":46},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":187,"slug":188,"hasResults":12,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":194,"targetDuration":4,"studyType":24,"phases":195,"briefSummary":197,"conditions":198,"keywords":200,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":47},"100600015","phase-4-a-trial-of-edaravone-dexborneol-in-acute-ischemic-stroke-with-active-malignancy-100600015","NCT07091994","A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy","A Prospective, Multicentre, Randomized Controlled Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy","PRECISE AM","Inclusion Criteria:\n\n* Age between 18 and 80 years (inclusive);\n* Diagnosis of acute ischemic stroke (AIS) according to the 2023 Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke;\n* Time from symptom onset to enrollment ≤48 hours;\n* Presence of focal neurological deficits with a baseline NIHSS score of 4-24, and a combined score of ≥2 points on NIHSS Item 5 (upper limb motor) and Item 6 (lower limb motor);\n* Confirmed active malignancy before stroke onset or during hospitalization, defined as: Cancer diagnosed within 12 months prior to stroke, Presence of metastatic disease, Received cancer-directed therapy within the past 30 days, or Patients who declined cancer treatment (still considered active malignancy);\n* Signed informed consent obtained from the patient or legally authorized representative.\n\nExclusion Criteria:\n\n* Intracranial hemorrhagic diseases detected on head CT: hemorrhagic stroke, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, etc;\n* Pre-stroke modified Rankin Scale (mRS) score \\>1;\n* Transient ischemic attack (TIA) as the current event;\n* Non-invasive skin cancers (e.g., basal cell carcinoma), primary central nervous system tumors, or hematologic malignancies;\n* Use of neuroprotective agents, including but not limited to: marketed edaravone, nimodipine, gangliosides, citicoline, piracetam, butylphthalide, human urinary kallidinogenase, or certain Chinese herbal medicines (see Concomitant Medications for details);\n* Patients with severe psychiatric disorders or dementia;\n* Hepatic or renal dysfunction: ALT or AST \\>3× upper limit of normal (ULN); Known liver diseases (e.g., acute\u002Fchronic active hepatitis, cirrhosis); Known kidney disease, renal insufficiency, serum creatinine \\>1.5×ULN, or creatinine clearance \\\u003C50 mL\u002Fmin;\n* Severe systemic diseases with an expected survival \\\u003C90 days;\n* Pre-stroke Eastern Cooperative Oncology Group (ECOG) performance status ≥3;\n* Hypersensitivity to edaravone, (+)-borneol, or any excipients;\n* Pregnancy, lactation, or planned pregnancy;\n* Participation in another clinical trial within 30 days prior to randomization or current enrollment in other interventional studies;\n* Any other condition deemed inappropriate for participation by the investigator.",{"count":144,"type":23},[196],"PHASE4","This multicenter randomized controlled trial aims to evaluate the efficacy and safety of edaravone dexborneol injection in patients with acute ischemic stroke (AIS) complicated by active malignancies. The study will primarily investigate whether this combined antioxidant and anti-inflammatory treatment can improve neurological functional recovery and assess its safety profile in this high-risk population. Investigators will compare outcomes between the edaravone dexborneol treatment group and a control group receiving standard therapy to determine if the intervention provides superior neuroprotective effects. Participants will receive the assigned treatment regimen, undergo serial neurological assessments and imaging studies to monitor stroke progression and recovery, and be closely followed for safety evaluations. The findings may offer evidence-based therapeutic options for managing this challenging clinical scenario where current treatment alternatives are limited.",[30,199],"Active Malignancies",[201,202,203,204],"active malignancies","ischemic stroke, acute","edaravone dexborneol","neuroprotection","2026-04-13",{"date":207,"type":39},"2026-04-16",{"date":209,"type":23},"2026-08-01",{"date":211,"type":23},"2026-12-31",{"name":213,"class":46},"Nanfang Hospital, Southern Medical University",{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":24,"phases":222,"briefSummary":223,"conditions":224,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":230,"leadSponsor":232,"locationsCount":4},"100633800","phase-3-safety-and-efficacy-of-remote-ischemic-conditioning-in-patients-with-acute-myocardial-injury-following-acute-ischemic-stroke-100633800","NCT07531394","Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Myocardial Injury Following Acute Ischemic Stroke","Inclusion Criteria:\n\n1. Age ≥ 18 years, regardless of sex;\n2. AIS confirmed by neuroimaging within 72 hours of symptom onset (or last known well time);\n3. Acute myocardial injury confirmed by serial measurements of plasma cardiac troponin (cTn) within 72 hours of symptom onset \\[19\\];\n4. Written informed consent provided by the participant or their legal authorized representative.\n\nExclusion Criteria:\n\n1. Pre-stroke mRS score ≥ 2;\n2. AIS patients receiving intravenous thrombolysis or endovascular thrombectomy;\n3. Definite history of coronary heart disease, severe valvular heart disease, arrhythmia, heart failure, cardiomyopathy, elevated cTn, and abnormal electrocardiogram (ECG) before onset;\n4. Suspicious cardiac-related symptoms (recurrent\u002Fpersistent chest pain\u002Fchest tightness\u002Fpalpitations, etc.) within 14 days before the index stroke;\n5. Any disorder that could potentially lead to elevated pre-stroke cTn: sepsis, acute kidney injury, rhabdomyolysis, major cardiac surgery or myocardial infarction, previous ischemic or hemorrhagic stroke, congestive heart failure, pulmonary embolism, deep vein thrombosis, endocarditis, severe anemia, thyroid dysfunction, Drug application, etc.;\n6. Patients who are planning for percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) for the index AMI within 3 months;\n7. Severe liver or kidney dysfunction or malignant tumors;\n8. Uncontrolled hypertension (systolic blood pressure ≥ 200mmHg at enrollment despite medication);\n9. Any limb deformity, vascular or soft tissue injury, orthopedic trauma, or other conditions affecting the implementation of RIC;\n10. Pregnancy or lactation period;\n11. Patients with psychiatric disorders or other reasons unable to cooperate with treatment and follow-up.",{"count":221,"type":23},580,[26],"Introduction: The management of acute myocardial injury following acute ischemic stroke (AMI-AIS), a frequent complication that severely worsens prognosis, is challenging. Remote ischemic conditioning (RIC) has demonstrated therapeutic potential in separate cardiac and cerebrovascular diseases, and preliminary single-center evidence suggests its safety and efficacy in patients with acute ischemic stroke (AIS) complicating acute myocardial infarction. Therefore, we propose to conduct a multicenter, randomized controlled trial to definitively evaluate the safety and efficacy of RIC in patients with AMI-AIS.\n\nMethods: This is a multicenter, randomized, double-blind, sham-controlled trial of 580 participants with AMI-AIS. Participants will be randomized to receive either the RIC procedures or sham RIC procedures twice daily for 14 consecutive days. A 3-month follow-up will be conducted to assess the safety and efficacy of RIC in AMI-AIS patients. The primary study outcome is the incidence of major adverse cardio-cerebrovascular events (MACCEs). The secondary outcomes include mortality, neurological and cardiac function, cerebral infarct volume, and cerebral perfusion.",[30,225],"Myocardial Injury","2026-04-09",{"date":228,"type":39},"2026-04-15",{"date":181,"type":23},{"date":231,"type":23},"2028-12-01",{"name":233,"class":46},"Capital Medical University",{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":24,"phases":243,"briefSummary":244,"conditions":245,"keywords":246,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":259},"100550097","mystroke-for-stroke-survivors-and-caregivers-100550097","NCT06442631","MyStroke for Stroke Survivors and Caregivers","An Individualized Video-based Stroke Education Platform for Stroke Survivors and Caregivers","Inclusion Criteria:\n\n* At least 18 years old\n* Admitted to hospital with clinical diagnosis of acute ischemic stroke (imaging confirmation not required)\n* Stroke symptom onset within 30 days of enrollment\n* Being discharged to either home or an acute rehabilitation facility\n* Access to internet enabled device (smartphone, tablet, computer)\n* Fluent in either English or Spanish (does not need to be native or primary language)\n* Willingness and ability to sign informed consent\n\nExclusion Criteria:\n\n* Severe aphasia (score of ≥2 on NIHSS item 9)\n* Ischemic stroke that is attributed to a surgical procedure\n* Resides in a skilled nursing facility prior to admission\n* Being discharged to skilled nursing facility or long-term acute care facility\n* Unwillingness or inability to participate in remote\u002Fvirtual study visits\n* A terminal or advanced condition that raises the possibility the subject may not survive 90 days\n* Any other illness or condition that the investigator feels would pose a hazard to the subject from participation in the study",{"count":242,"type":23},690,[86],"The goal of this multicenter randomized trial is to evaluate the impact of a personalized video-based stroke education platform on patient-centered and health system-centered outcomes. The main questions this study aims to address are:\n\n1. Does a personalized, video-based educational platform improve stroke knowledge?\n2. Does a personalized, video-based educational platform reduce post-discharge health system utilization?\n3. Do different strategies of nudging improve engagement with educational material after hospital discharge?\n\nIn order to determine the effect of this personalized stroke education strategy, researchers will compare subjects who receive standard stroke education with those who receive the personalized stroke education platform in addition to standard standard education. Patient knowledge will be assessed 90-days after discharge. Study participants will include both stroke patients and caregivers, who will:\n\n1. Receive standard education during the stroke hospitalization\n2. Complete a survey on the day of hospital discharge to assess their baseline knowledge.\n3. Half of the subjects will be randomly assigned to also receive access to the personalized stroke education platform on the day of discharge.\n4. All subjects will complete two follow-up study visits (7 and 90 days after discharge) in order to complete surveys.",[89,30],[247,248,249],"stroke education","ischemic stroke","stroke knowledge","2026-01-05",{"date":252,"type":39},"2026-01-08",{"date":254,"type":23},"2026-03-01",{"date":256,"type":23},"2030-03-01",{"name":258,"class":46},"University of Pennsylvania",5,{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":266,"targetDuration":4,"studyType":24,"phases":268,"briefSummary":269,"conditions":270,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":278,"locationsCount":47},"100565221","effects-of-transcranial-magnetic-stimulation-after-endovascular-treatment-for-acute-ischemic-stroke-100565221","NCT06639360","Effects of Transcranial Magnetic Stimulation After Endovascular Treatment for Acute Ischemic Stroke","Inclusion Criteria:\n\n1. Patients with acute anterior circulation ischemic stroke aged between 18 and 80 years old.\n2. Imaging suggests that the infarction is caused by occlusion of the terminal portion of the internal carotid artery or the M1\u002FM2 segment of the middle cerebral artery.\n3. A head CT within 24 hours of onset indicates an ASPECT score ≥6, and meets the guideline-recommended criteria for thrombectomy.\n4. Pre-stroke mRS score is ≤1.\n5. NIHSS score before thrombectomy is between 6 and 25.\n6. With vascular recanalization of mTICI \\> 2b\u002F3.\n7. Informed consent form signed.\n\nExclusion Criteria:\n\n1. Patients with contraindications to TMS treatment, such as those with metallic foreign objects in the head, pacemakers, implantable drug pumps, cochlear implants, etc.;\n2. Patients with epilepsy, increased intracranial pressure, tumors, acute cerebral hemorrhage, or other severe neurological diseases, and those with severe functional impairment of organs such as the heart, liver, and kidneys;\n3. Head CT\u002FMRI indicates midline shift or significant mass effect, or patients planned for surgical intervention;\n4. Head CT\u002FMRI suggests acute cerebral infarction in both sides;\n5. Patients who are pregnant or breastfeeding;\n6. Patients with severe mental disorders or dementia who cannot cooperate with follow-up;\n7. Patients with other severe diseases resulting in an expected survival of less than 90 days;\n8. Patients who are participating in other interventional clinical studies within 30 days before the start of this study or after the onset of this condition;\n9. Patients who cannot cooperate with informed consent.",{"count":267,"type":23},60,[86],"This is a multicenter, randomized, double-blind, sham-controlled trial, to determine the efficacy and safety of cTBS in treating patients with acute ischemic stroke after endovascular treatment.",[30,271],"Endovascular Thrombectomy","2025-11-26",{"date":274,"type":39},"2025-12-04",{"date":276,"type":39},"2025-08-02",{"date":211,"type":23},{"name":279,"class":46},"Xijing Hospital",{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":12,"sex":18,"minAge":287,"maxAge":288,"enrollmentInfo":289,"targetDuration":4,"studyType":24,"phases":291,"briefSummary":292,"conditions":293,"keywords":295,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":47},"100571952","effect-of-exercise-gene-expression-and-histone-modifications-in-patients-with-hemiplegia-100571952","NCT06726941","Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia","Effect of Exercise on Neuroplasticity-Related Gene Expression and Histone Modifications in Patients With Hemiplegia","Inclusion Criteria:\n\n1. Participants who applied to Afyonkarahisar Health Sciences University Physical Therapy and Rehabilitation Clinic for rehabilitation purposes and had a stroke for the first time\n2. Participants with ischemia as the etiology of stroke\n3. Participants between the ages of 25-70\n4. Drugs that have been used for at least 1 month and up to 6 months after a cerebrovascular accident\n\nExclusion Criteria:\n\n1. Participants whose stroke etiology is other than ischemia\n2. Participants with clinically significant neurological disease other than stroke\n3. Participants with systemic and musculoskeletal diseases that will not tolerate neurological rehabilitation and prevent them from participating","25 Years","70 Years",{"count":290,"type":23},48,[86],"The aim of this study is to demonstrate the effect of routine exercise program on neuroplasticity through histone acetylation and gene expression changes in acute stroke survivors from an epigenetic perspective and to investigate the correlation of epigenetic effects with its effects on motor function and quality of life.",[30,294],"Acute Hemiparesis",[248,296,297],"acute hemiplegia","epigenetics","2025-11-22",{"date":300,"type":39},"2025-11-25",{"date":302,"type":39},"2024-12-20",{"date":304,"type":23},"2026-09-09",{"name":306,"class":46},"Afyonkarahisar Health Sciences University",{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":316,"phases":4,"briefSummary":317,"conditions":318,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":4},"100611041","predictors-of-post-thrombectomy-cognitive-impairment-in-acute-ischemic-stroke-patients-100611041","NCT07235423","Predictors of Post-Thrombectomy Cognitive Impairment in Acute Ischemic Stroke Patients","Predictors of Post-Thrombectomy Cognitive Impairment in Acute Ischemic Stroke Patients : a Prospective Cohort Study","Inclusion Criteria:\n\n1. Adults (≥18 years).\n2. Acute ischemic stroke due to anterior circulation LVO confirmed by imaging undergoing EVT per guidelines.\n3. Successful reperfusion (mTICI 2b-3)\n4. Able to provide consent.\n\nExclusion Criteria:\n\n1. Severe aphasia\u002Fcoma interfering with cognitive assessment.\n2. Pre-existing dementia ( using Arabic version of the Short Form of the Informant Questionnaire on Cognitive Decline in the Elderly).\n3. Non-ischemic etiology.\n4. Death within 72 hours.\n5. Refusal to participate in the study.",{"count":315,"type":23},120,"OBSERVATIONAL","This prospective cohort study investigates predictors of post-stroke cognitive impairment (PSCI) in patients undergoing endovascular thrombectomy (EVT) for acute ischemic stroke due to large vessel occlusion. Adult patients with successful reperfusion (mTICI 2b-3) will be followed at 3 and 6 months to assess cognition, functional recovery, and depression. Predictors across clinical, procedural, radiological, and laboratory domains will be analyzed. The study aims to identify risk factors for PSCI, estimate its prevalence, and evaluate its impact on outcomes.",[30],"2025-11-17",{"date":321,"type":39},"2025-11-19",{"date":323,"type":23},"2025-12-01",{"date":325,"type":23},"2028-01-15",{"name":327,"class":46},"Assiut University",{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":334,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":24,"phases":338,"briefSummary":339,"conditions":340,"keywords":344,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":47},"100443207","phase-2-co2-modulation-in-endovascular-thrombectomy-for-acute-ischemic-stroke-100443207","NCT05051397","CO2 Modulation in Endovascular Thrombectomy for Acute Ischemic Stroke","Evaluation of the Effect of Moderate and Controlled Hypercapnia on Ischemic Penumbra Vascular Collaterality During General Anesthesia for Anterior Circulation Acute Ischemic Stroke Mechanical Thrombectomy","COMET-AIS","Inclusion Criteria:\n\n• Large vessel occlusion anterior circulation stroke (terminal carotid artery and\u002For middle cerebral artery M1-M2 segment) eligible to mechanical thrombectomy under general anesthesia\n\nExclusion Criteria :\n\n* Active smoker\n* Chronic respiratory failure with ambulatory oxygen supplementation\n* Obesity with BMI\\>40Kg\u002F m2\n* Intubation before the procedure\n* Heart failure with intolerance to decubitus\n* Severe renal failure\n* Suspected elevated intracranial pressure\n* Pregnant or breastfeeding women",{"count":337,"type":23},50,[116],"Acute ischemic stroke due to large vessel occlusion is responsible of cerebral blood flow impairment with a progressive and extensive ischemic process. Cerebral collateral circulation may preserve an ischemic penumbra that could recover providing timely reperfusion of the occluded vessel. Mechanical thrombectomy is the standard of care for anterior circulation large vessel reperfusion. Strategy to promote cerebral blood flow in collateral circulation before reperfusion is scarce and rely mainly on blood pressure maintenance. Carbon dioxide is a potent cerebral vasodilator that could enhance collateral circulation blood flow and cerebral protection before reperfusion. General anesthesia with endotracheal mechanical ventilation could be used for thrombectomy and give the opportunity to modulate and control carbon dioxide tension in the blood. This study will test the effect of moderate hypercapnia on penumbral collateral circulation before reperfusion during mechanical thrombectomy for anterior circulation acute ischemic stroke under general anesthesia.",[30,125,341,342,343],"Anesthesia, General","Cerebrovascular Circulation","Carbon Dioxide",[345,346,347,348,349,350],"mechanical thrombectomy","large vessel occlusion stroke","carbon dioxide tension","cerebral blood flow","general anesthesia","cerebral collateral circulation","2025-09-30",{"date":353,"type":39},"2025-10-06",{"date":355,"type":39},"2022-07-20",{"date":357,"type":23},"2026-10-19",{"name":359,"class":46},"University Hospital, Clermont-Ferrand",{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":368,"targetDuration":370,"studyType":316,"phases":4,"briefSummary":371,"conditions":372,"keywords":373,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":4},"100607994","expansion-floating-craniotomy-for-the-treatment-of-malignant-cerebral-edema-caused-by-acute-ischemic-stroke-100607994","NCT07195786","Expansion-floating Craniotomy for the Treatment of Malignant Cerebral Edema Caused by Acute Ischemic Stroke","Expansion-floating Craniotomy for the Treatment of Malignant Cerebral Edema Caused by Acute Ischemic Stroke--A Prospective, Multicenter, Non-inferiority,Cohort Study（ECAIS）","ECAIS","Inclusion Criteria:\n\n* Age requirement: Adults aged \\>18 but \\\u003C80 years\n* Acute cerebral infarction diagnosis: Patients with internal carotid artery or middle cerebral artery occlusion within 48 hours, meeting all three criteria:\n\nNIHSS score ≥16 with item 1a (level of consciousness) ≥1 CT demonstrating \\>50% MCA territory infarction or hypoperfused area \\>2\u002F3, OR DWI hyperintensity volume \\>82 ml within 6 hours of onset, OR DWI infarct volume \\>145 ml within 14 hours\n\n* Imaging evidence: Midline shift ≥5 mm to the contralateral side on CT, OR significant ipsilateral ventricular compression with effacement of cerebral sulci\u002Fcisterns.\n\nExclusion Criteria:\n\n* Pre-stroke mRS score ≥1\n* Significant contralateral cerebral infarction\n* Symptomatic intracranial hemorrhage\n* Any known coagulopathy\n* Life expectancy \\\u003C3 years\n* Any severe comorbidities potentially interfering with treatment evaluation",{"count":369,"type":23},356,"3 Months","This clinical study investigates Expansion-floating Craniotomy (EC), a novel surgical technique for treating life-threatening malignant cerebral edema following large hemispheric infarction (commonly known as massive stroke). Malignant edema causes rapid increases in intracranial pressure, compressing vital brain structures and risking fatal brain herniation, requiring urgent intervention.\n\nThe current international standard treatment is traditional decompressive craniectomy (DC). DC involves removing a section of the skull to allow brain swelling, effectively reducing pressure and mortality risk. It is strongly recommended (Class I, Level A evidence) in major guidelines. However, DC typically requires a second major surgery (cranioplasty) approximately 3 months later to replace the removed bone flap, involving additional costs and risks like progressive intracranial hemorrhage or subdural hygroma.\n\nEC is a newer approach designed to potentially eliminate the need for a second surgery. During EC, surgeons use medical titanium plates to temporarily elevate the bone flap, creating immediate space for brain swelling while keeping the bone flap attached. Once brain swelling subsides (usually within weeks), a minor procedure flattens the titanium plates, allowing the patient's own bone to naturally reposition without requiring cranioplasty. EC may be performed based on surgeon assessment of brain swelling, guideline considerations, or experience. If EC is deemed unsuitable during surgery, DC will be performed instead.\n\nWhile early research suggests EC achieves decompression similar to DC while preserving the bone flap, its safety and effectiveness compared to the established DC procedure are not yet fully proven. DC is a well-understood, mature technique with known risks and benefits, including the certainty of needing cranioplasty. Conservative management is reserved for patients unfit for surgery but may not prevent neurological deterioration.This study aims to conduct a preliminary assessment of the outcomes of EC versus DC.",[30,175],[374,175,375,376],"Expansion-floating Craniotomy","decompressive craniectomy","Acute Ischemic Stroke","2025-09-24",{"date":379,"type":39},"2025-09-29",{"date":381,"type":23},"2025-10-01",{"date":383,"type":23},"2027-05-30",{"name":385,"class":46},"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University",{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":392,"eligibilityCriteria":393,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":394,"enrollmentInfo":395,"targetDuration":4,"studyType":24,"phases":397,"briefSummary":398,"conditions":399,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":47},"100606445","methylprednisolone-sodium-succinate-with-endovascular-thrombectomy-for-large-ischemic-stroke-100606445","NCT07175649","Methylprednisolone Sodium Succinate With Endovascular ThRombectomy for Large Ischemic STroke","Methylprednisolone Sodium Succinate With Endovascular ThRombectomy for Large Ischemic STroke: A Randomized, Double-blind, Placebo-controlled Trial","PEARL-MERIT","Inclusion Criteria:\n\n* Aged 18 to 85 years;\n* Clinically diagnosed acute ischemic stroke with screening NIHSS ≥6;\n* Time from last known well to randomization ≤24 hours;\n* Pre-stroke mRS score of 0-1;\n* Occlusion of the responsible vessel confirmed by CT angiography (CTA), magnetic resonance angiography (MRA), or digital subtraction angiography (DSA) in intracranial segment of internal carotid artery (ICA), M1 or M2 segment of middle cerebral artery (MCA), and plan to undergo EVT;\n* Alberta Stroke Program Early CT Score (ASPECTS) of 0-5 on NCCT, or ischemic core volume ≥70 mL (defined as regional cerebral blood flow \\[rCBF\\] \\\u003C30% on CT perfusion \\[CTP\\] or apparent diffusion coefficient \\[ADC\\] \\\u003C620×10-⁶ mm²\u002Fs on MRI);\n* Informed consent obtained.\n\nExclusion Criteria:\n\n* Intracranial hemorrhage on NCCT or MRI;\n* Allergy to corticosteroids;\n* Allergy to contrast agents;\n* Severe infectious disease unsuitable for corticosteroid therapy or concurrent contraindications to corticosteroid treatment;\n* Random blood glucose \\>22.2 mmol\u002FL (400 mg\u002FdL);\n* Known hereditary or acquired bleeding diathesis, coagulation factor deficiency, use of warfarin with an international normalized ratio (INR) \\>1.7, or administration of novel oral anticoagulants within 48 hours of symptom onset;\n* Platelet count \\\u003C90×10⁹\u002FL;\n* History of gastrointestinal or urinary tract bleeding within the last month;\n* Current participation in another interventional clinical trial;\n* Pregnancy or lactating;\n* Renal dysfunction with an estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin or serum creatinine \\>220 μmol\u002FL (2.5 mg\u002FdL);\n* Persistent systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg despite antihypertensive treatment;\n* Life expectancy \\\u003C6 months due to terminal illnesses such as malignancy or severe cardiopulmonary disease;\n* Intracranial aneurysm or arteriovenous malformation;\n* Intracranial tumour with mass effect on imaging (except for small meningiomas);\n* Other conditions deemed unsuitable for study participation by the investigator, including inability to comprehend and\u002For comply with study procedures and\u002For follow-up due to psychiatric, cognitive, or emotional disorders.","85 Years",{"count":396,"type":23},912,[86],"It is uncertain whether intravenous methylprednisolone improves outcomes for acute anterior circulation large vessel occlusion (LVO) patients with a large infarct core. In this study, the investigators hypothesize that methylprednisolone plus endovascular thrombectomy (EVT) might be superior to EVT alone in patients with evidence of a large infarct volume. The primary objective of the study is to establish the efficacy of methylprednisolone with EVT in patients with acute anterior circulation LVO and a large infarct core.",[30],"2025-09-09",{"date":402,"type":39},"2025-09-16",{"date":404,"type":23},"2025-10",{"date":406,"type":23},"2029-12",{"name":408,"class":46},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":4,"eligibilityCriteria":415,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":416,"targetDuration":4,"studyType":316,"phases":4,"briefSummary":418,"conditions":419,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":47},"100521902","long-term-outcomes-of-laa-contrast-flow-in-ct-scans-after-endocardial-laa-closure-the-cf-ct-registry-100521902","NCT06075628","Long-Term Outcomes of LAA Contrast Flow in CT Scans After Endocardial LAA Closure: The CF-CT Registry","Long-Term Outcomes of Left Atrial Appendage Contrast Flow in CT Scans After Endocardial LAA Closure: The CF-CT Registry","Inclusion Criteria:\n\n* Subjects must be at least 18 years of age.\n* Subjects underwent LAA closure with Watchman\u002FWatchman FLX or Amplatzer Amulet at our institution from January 2019 till June 2022\n\nExclusion Criteria:\n\n* No definite exclusion criteria are defined for the study as all patients with Watchman-FLX or Amplatzer Amulet will be included in the study.",{"count":417,"type":23},100,"This study is intended to assess the incidence and correlation to the development of peri-device leaks (PDLs), device related thrombosis (DRTs) and cerebral vascular accident (CVA)\u002Ftransient ischemic attacks (TIAs) in association with left atrial appendage contrast flow (LAA-CF). It will be a multi-center, retrospective study. Approximately 100 subject charts will be reviewed.",[420,30],"Atrial Fibrillation","2025-08-27",{"date":423,"type":39},"2025-08-28",{"date":425,"type":39},"2023-07-24",{"date":427,"type":23},"2025-12",{"name":429,"class":46},"Kansas City Heart Rhythm Research Foundation",{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":436,"eligibilityCriteria":437,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":438,"targetDuration":4,"studyType":24,"phases":440,"briefSummary":442,"conditions":443,"keywords":444,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":451,"completionDateStruct":452,"leadSponsor":454,"locationsCount":4},"100603997","phase-1-human-induced-neural-stem-cell-derived-exosomes-for-treating-acute-ischemic-stroke-100603997","NCT07143786","Human Induced Neural Stem Cell-derived Exosomes for Treating Acute Ischemic Stroke","Human Induced Neural Stem Cell-derived Exosomes for Treating Acute Ischemic Stroke: an Exploratory Clinical Trial","NSAIS","Inclusion Criteria:\n\n1. Aged 18-80 years (inclusive), regardless of gender;\n2. Clinically diagnosed with an anterior circulation ischemic stroke in the current episode, confirmed by head MRI\u002FCT, and able to receive the investigational product within 1 week after symptom onset;\n3. National Institutes of Health Stroke Scale (NIHSS) score of 6-20 (inclusive) at randomization, with NIHSS item Ia score \\\u003C2, and a change in NIHSS score from baseline to randomization of \\\u003C4 points;\n4. Female subjects of childbearing potential, or male subjects with partners of childbearing potential, must have no plans for pregnancy during the study and voluntarily use effective contraception;\n5. Modified Rankin Scale (mRS) score of 0 or 1 before the onset of the current stroke symptoms, as self-reported or reported by family members.\n6. All subjects, or their legal guardians, must provide written informed consent after receiving full information about the study and voluntarily participate in this clinical trial.\n\nExclusion Criteria:\n\n1. Those with epilepsy, Alzheimer's disease, Parkinson's disease, severe depression, or other neurological disorders or psychiatric illnesses that the investigator deems would impair their ability to participate in the trial or affect the assessment of the study;\n2. Patients who have experienced hemorrhagic transformation after the current ischemic stroke and are deemed unsuitable for participation in the clinical trial by the investigator;\n3. Patients with malignant tumors, except for those with low-grade malignant tumors such as basal cell carcinoma, papillary thyroid carcinoma, and localized prostate cancer in situ, who have received radical treatment for more than five years;\n4. Patients with severe infections, including sepsis, septic shock, severe pneumonia (refer to the 2007 criteria for severe pneumonia in adults by the Infectious Diseases Society of America\u002FAmerican Thoracic Society for the diagnosis of severe pneumonia);\n5. Patients with respiratory failure, or those with current evidence of pulmonary embolism or suspected pulmonary embolism;\n6. Patients whose organ function meets any one or more of the following criteria:\n\n   1. Absolute Neutrophil Count (ANC) \\\u003C 1.5 × 10⁹\u002FL, Platelets (PLT) \\\u003C 100 × 10⁹\u002FL;\n   2. Hemoglobin (Hb) \\\u003C 90 g\u002FL;\n   3. Aspartate Aminotransferase (AST) \\> 2.5 × Upper Limit of Normal (ULN) and\u002For Alanine Aminotransferase (ALT) \\> 2.5 × ULN, Total Serum Bilirubin (TBIL) \\> 1.5 × ULN;\n   4. Creatinine \\> 1.5 × ULN;\n   5. For patients not receiving anticoagulant or antithrombotic therapy: International Normalized Ratio (INR) \\> 1.7 or Activated Partial Thromboplastin Time (APTT) \\> 1.25 × ULN; for patients receiving anticoagulant or antithrombotic therapy: INR \\> 3.0 or APTT \\> 1.5 × ULN;\n7. Patients with a history of or current severe cardiovascular diseases:\n\n   1. Those with myocardial ischemia, myocardial infarction, or unstable angina pectoris graded above CTCAE (Common Terminology Criteria for Adverse Events) Grade II;\n   2. Severe arrhythmias deemed clinically significant by the investigator;\n   3. Cardiac insufficiency of NYHA (New York Heart Association) Class III-IV;\n   4. Those with other acute severe life-threatening complications;\n8. Patients with poorly controlled hypertension (defined as persistent systolic blood pressure \\> 220 mmHg or diastolic blood pressure \\> 120 mmHg despite antihypertensive treatment);\n9. Patients with poorly controlled diabetes mellitus (defined as blood glucose remaining \\> 16.8 mmol\u002FL despite treatment) or hypoglycemia (blood glucose \\\u003C 2.8 mmol\u002FL);\n10. Patients with a history of immunodeficiency, including: HIV-positive status, other acquired or congenital immunodeficiency diseases, idiopathic IgA deficiency, or those who have received systemic corticosteroid therapy (≥ 10 mg\u002Fday prednisone equivalent) or immunosuppressive drug therapy within 14 days prior to receiving the study drug, or who are expected to require such therapy during the trial;\n11. Patients positive for Hepatitis B surface antigen (HBsAg) or Hepatitis B core antibody (HBcAb) with positive HBV-DNA, positive Hepatitis C antibody (HCV), or positive Treponema pallidum antibody (TPAb\u002FRPR);\n12. Patients who have participated in other drug clinical trials within 3 months prior to screening;\n13. Patients with known allergies to the study drug or any of its components (e.g., human serum albumin);\n14. Patients unable to undergo cranial CT\u002FMRI examinations for any reason;\n15. Patients who have undergone major surgery, suffered severe trauma within 3 months prior to the first dose, or plan to undergo surgery that may affect neurological function assessment during the trial;\n16. Pregnant or lactating patients;\n17. Patients with other severe systemic diseases, or a history of any diseases or laboratory abnormalities that may confound study results, interfere with the subject's participation in study procedures, or are not in the subject's best interest to participate, and who are deemed unsuitable for enrollment by the investigator.",{"count":439,"type":23},38,[441,116],"PHASE1","A phase I\u002FIIa clinical trial investigating the safety and preliminary efficacy of intravenous administration of human induced neural stem cell-derived exosomes for acute ischemic stroke",[30],[445,446,33,447,448],"induced neural stem cell","exosome","safety","efficacy","2025-08-19",{"date":421,"type":39},{"date":381,"type":23},{"date":453,"type":23},"2027-12-31",{"name":455,"class":46},"Xuanwu Hospital, Beijing",{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":460,"acronym":4,"eligibilityCriteria":461,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":462,"targetDuration":4,"studyType":24,"phases":464,"briefSummary":465,"conditions":466,"keywords":468,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":480,"locationsCount":47},"100458246","phase-4-the-role-of-circadian-factors-in-regulation-of-neuroplasticity-in-ischemic-stroke-interventional-100458246","NCT05247125","The Role of Circadian Factors in Regulation of Neuroplasticity in Ischemic Stroke (Interventional)","Inclusion Criteria:\n\n* acute (symptom onset to admission \\\u003C1 days) ischemic stroke\n* ischemic stroke affecting the branches of anterior cerebral artery, middle cerebral artery and posterior cerebral artery\n* age 18-80 years\n* moderate or severe stroke (National Institutes of Health Stroke Scale, NIHSS\\>=5)\n* intravascular stroke treatment with thrombolysis or thrombectomy leading to satisfactory reperfusion (if applicable)\n* informed consent\n\nExclusion Criteria:\n\n* secondary parenchymal hemorrhage (\\>hemorrhage index (HI)-2)\n* clinically unstable or life-threatening conditions\n* previous stroke in the last 6 months\n* known progressive neurological diseases\n* known psychiatric diseases\n* concomitant benzodiazepine medication\n* drug or alcohol abuse\n* pregnancy\n* inability to participate in the study\n* severe sensory aphasia\n* melatonin intake at\u002Fbefore admission\n* light therapy use at\u002Fbefore admission\n* blindness\n* severe sleep-disordered breathing (apnea-hypopnea index \\>=30\u002Fh)\n* contraindications to light therapy (severe retinopathy, epilepsy, porphyria, intake of drugs with photosensitizing effects)\n* contraindications to melatonin intake (severe bronchial asthma, severe autoimmune disorders, chronic kidney disease 3b stage and higher, leukosis)\n* congestive heart failure with reduced ejection fraction (\\\u003C=45%) or New York Heart Association (NYHA) classification III-IV functional class.",{"count":463,"type":23},80,[196],"There is a lack of complex studies which could establish the association between genetic circadian factors with the features and short-term outcomes of ischemic stroke, as well as the effects of various auxiliary therapies for circadian rhythm modulation for neuroplasticity enhancement and improvement of short-term outcomes in ischemic stroke.\n\nThe main research hypothesis is that circadian factors influence the recovery from ischemic stroke via sleep-mediated regulation of synaptic plasticity.\n\nThe project aims at the investigation of the influence of combined melatonin therapy and blue light exposure on molecular circadian biomarkers, sleep characteristics, neuroplasticity markers and stroke outcome in acute stroke patients.\n\nThis study is a prospective, interventional, randomized placebo-controlled trial.",[30,467],"Sleep Disorders, Circadian Rhythm",[469,470,471,472,473],"circadian misalignment","neuroplasticity","melatonin","light therapy","circadian disorder","2025-08-05",{"date":476,"type":39},"2025-08-08",{"date":478,"type":39},"2022-03-01",{"date":211,"type":23},{"name":481,"class":46},"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":486,"acronym":487,"eligibilityCriteria":488,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":489,"targetDuration":4,"studyType":316,"phases":4,"briefSummary":491,"conditions":492,"keywords":494,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":47},"100600600","image-detection-of-impaired-microcirculatory-reperfusion-100600600","NCT07099599","Image Detection of Impaired Microcirculatory Reperfusion","ID IMR","Inclusion Criteria:\n\n* Adults greater than or equal to 18 years of age\n* Last known normal (LKN) within 24 hours\n* Ischemic stroke due to anterior circulation LVO (intracranial internal carotid artery \\[ICA\\], proximal middle cerebral artery \\[M1\\], M1\u002FM2 bifurcation, or proximal dominant M2 occlusion)\n* mTICI2c or mTICI3 on digital subtracted angiography (DSA) following mechanical thrombectomy\n\nExclusion Criteria:\n\n* Significant renal insufficiency (glomerular filtration rate \\<30mg\u002Fml\u002Fmin2 while not on dialysis)\n* Contraindication to iodinated contrast\n* Contraindication to magnetic resonance imaging (e.g., pacemaker incompatibility)\n* Prior significant stroke in same vascular territory ipsilateral stroke\n* Tandem vessel occlusion (i.e., extracranial ICA and ipsilateral intracranial M1\u002FM2 occlusion)\n* Greater than 4 clot retrieval attempts\n* Enrollment in another acute stroke interventional study (with the exception of thrombectomy device registries)\n* Pregnancy\n* Prisoners",{"count":490,"type":23},40,"Stroke affects one patient every 40 seconds in the United States. It is most commonly caused by blood clots that develop in the blood vessels of the brain. These blood clots interrupt the normal flow of blood and oxygen to the nerve cells in the brain. When this occurs, the nerve cells can die, causing permanent damage to that area of the brain. That damage can result in loss of normal function to a patient's vision, strength, sensation, balance, or speech. These changes can remain permanent if blood flow is not restored to the brain. Thankfully, there are treatments available to help get rid of these blood clots. One of these treatments is a procedure to physically remove the blood clot causing stroke. This practice is now routinely done at all major stroke centers.\n\nSpecial imaging for stroke is now available at these major stroke centers. This imaging looks at blood flow in and around the area of brain that is dying. By performing these scans after the procedure, we can see that not all of brain is being saved by the procedure. That is a problem, because we know that saving brain cells can make a big difference in how patients recover from stroke. The purpose of this study is to determine which brain tissue will not get saved by blood clot removal. We will do this by using specialized imaging after the procedure. The study will discover if there is more brain tissue that can be saved after the procedure. Once we can determine this, our next steps will be looking at ways to save this tissue in the studies that follow. For example, we will look to see if medications can be given after the procedure to help save those brain areas. This study lays the groundwork for future studies to help save all the brain tissue we possibly can from dying during the stroke. This is our best chance of getting all patients affected by stroke the opportunity to live their best lives after stroke.",[30,493],"Large Vessel Occlusion",[495,496,62],"No Reflow","Microcirculatory Reperfusion","2025-07-25",{"date":499,"type":39},"2025-08-01",{"date":501,"type":39},"2024-09-30",{"date":503,"type":23},"2027-03-31",{"name":505,"class":46},"University of Cincinnati",{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":4,"eligibilityCriteria":512,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":513,"enrollmentInfo":514,"targetDuration":4,"studyType":24,"phases":516,"briefSummary":517,"conditions":518,"keywords":519,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":531,"locationsCount":533},"100528187","phase-3-shuxuening-injection-in-the-treatment-with-intravenous-thrombolysis-in-patients-with-ischemic-stroke-shiny-100528187","NCT06157502","Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY)","Efficacy and Safety of Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke: A Multicenter, Randomized, Double-blind, Placebo-parallel Controlled Trial","Inclusion Criteria:\n\n* Age 18 or older;\n* Diagnosed with acute ischemic stroke;\n* Within 6 hours of onset;\n* Having received or plan to undergo intravenous thrombolytic therapy;\n* NIHISS score of 4 to 25 points at enrollment;\n* Signed informed consent.\n\nExclusion Criteria:\n\n* mRS score greater than 1 point before the onset;\n* Receiving neuroprotective agents, such as edaravone, edaravone dextrocamphorol, butylphthalein, etc. after the onset;\n* Bleeding or other pathological brain disorders, such as vascular malformations, tumors, abscesses, or other common non-ischemic brain diseases (such as multiple sclerosis), detected by CT\u002FMRI;\n* History of clotting disorders, systemic bleeding, thrombocytopenia, or neutropenia;\n* Severe hepatic or renal insufficiency (severe hepatic insufficiency refers to the ALT or AST levels above 3 times the upper limit of normal; severe renal insufficiency refers to the creatinine levels above 2 times the upper limit of normal);\n* Allergic to Shuxuening injection or preparations containing ginkgo biloba (ginkgo biloba extract);\n* Women who are pregnant or breastfeeding, and women of childbearing age who have a negative pregnancy test but refuse to take effective contraceptive measures;\n* Participation in another clinical trial with an experimental product during the last 30 days;\n* Other participants deemed unsuitable for participation in this study by the investigator.","100 Years",{"count":515,"type":23},1380,[26],"Shuxuening injection is a multi-target neuroprotective agent, it is expected to play a neuroprotective role on the basis of intravenous thrombolysis therapy. The primary purpose of this multicenter, randomized, double-blind, placebo-parallel controlled trial is to evaluate the efficacy and safety of Shuxuening injection in the treatment with intravenous thrombolysis in patients with ischemic stroke.",[30],[62,520,521,522,523],"Intravenous Thrombolysis","Neuroprotective Therapy","Shuxuening Injection","Randomized Controlled Trial","2025-07-21",{"date":526,"type":39},"2025-07-24",{"date":528,"type":39},"2024-01-11",{"date":530,"type":23},"2026-07-31",{"name":532,"class":46},"Beijing Tiantan Hospital",82,{"id":535,"slug":536,"hasResults":12,"nctId":537,"briefTitle":538,"officialTitle":539,"acronym":540,"eligibilityCriteria":541,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":394,"enrollmentInfo":542,"targetDuration":4,"studyType":24,"phases":544,"briefSummary":545,"conditions":546,"keywords":547,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":558,"locationsCount":47},"100476705","phase-4-effects-of-minocycline-on-patients-with-ischemic-stroke-undergoing-intravenous-thrombectomy-100476705","NCT05487417","Effects of Minocycline on Patients With Ischemic Stroke Undergoing Intravenous Thrombectomy","Effects of Minocycline on Patients With Acute Anterior Circulation Ischemic Stroke Undergoing Intravenous Thrombectomy","MIST-A","Inclusion Criteria:\n\n1. Patients with acute cerebral infarction of anterior circulation accompanied by large vessel occlusion;\n2. Age 18-85 years old;\n3. The time of onset ≤ 6 hours or ≤ 24 hours suitable for mechanical thrombectomy determined by multimodal imaging;\n4. The time of onset 6-24 hours, DWI shows an infarct volume less than 1\u002F3 of the MCA blood supply area; the time of onset ≤ 6 hours, the ASPECTS(Alberta Stroke Program Early CT Score) is ≥6;\n5. Preoperative NIHSS score ranges from 6 to 30 points;\n6. Sign the informed consent form;\n\nExclusion Criteria:\n\n1. There are contraindications for mechanical thrombectomy;\n2. No revascularization therapy was performed during the operation or the TICI score after revascularization therapy was less than 2b;\n3. There are other major central nervous system diseases, such as brain injury, brain tumor, multiple sclerosis, etc;\n4. There is evidence that the patient has bacterial endocarditis, aortic dissection, arteritis or venous cerebral infarction;\n5. Renal insufficiency or hepatic insufficiency (serum creatinine \\>2.0 mg\u002FdL or 180 µmol\u002FL; liver function greater than 3 times the normal value);\n6. Known history of congestive heart failure (requiring dietary or medication changes or hospitalization) within 6 months, or myocardial infarction within 6 months;\n7. There is evidence of any other life-threatening or severe diseases that may hinder the completion of the 3-month follow-up and affect the evaluation of the results;\n8. Pre-existing neurological deficits or history of dementia;\n9. There are infectious diseases that require antibiotic treatment before the disease;\n10. Allergic to tetracyclines or unable to take minocycline for other reasons;\n11. Minocycline could not be given within 1 hour after recanalization;\n12. Pregnant patients;\n13. Participated in another clinical trial within 30 days before inclusion in the study.\n14. Refuse to sign the informed consent form.",{"count":543,"type":23},180,[196],"Minocycline is the second generation of tetracycline. Because of its lipophilicity, it has high penetrance of blood-brain barrier. Animal model studies have shown that minocycline can reduce cerebral damage after ischemic stroke, and its mechanism involves multiple molecular pathways, such as antioxidant, anti-inflammatory, anti apoptotic pathways, and protection of blood-brain barrier. Clinical studies have also shown that minocycline can significantly improve 3-month National Institute of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS) of patients with ischemic stroke, indicating that minocycline is a potential neuroprotective drug. Minocycline is believed to protect the blood-brain barrier, thereby reducing the ischemia-reperfusion injury caused by mechanical thrombectomy. However, whether minocycline can become a synergistic treatment method of mechanical thrombectomy, there is no clinical research in this area at present. Therefore, investigators carry out the study on the effect of minocycline in patients with acute anterior circulation ischemic stroke after mechanical thrombectomy, and plan to enroll 180 patients. To explore the safety and effectiveness of minocycline in patients with acute ischemic stroke after thrombectomy.",[30],[62,548,549,550,551],"Minocycline","Mechanical thrombectomy","Anterior circulation","Neuroprotection","2025-07-20",{"date":526,"type":39},{"date":555,"type":39},"2022-11-01",{"date":557,"type":23},"2025-09-10",{"name":279,"class":46},{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":565,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":567,"targetDuration":4,"studyType":24,"phases":568,"briefSummary":569,"conditions":570,"keywords":573,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":582,"locationsCount":47},"100570804","phase-2-a-dose-response-controlled-trial-of-bevifibatide-for-acute-ischemic-stroke-100570804","NCT06712004","A Dose-Response Controlled Trial of Bevifibatide for Acute Ischemic Stroke","Efficacy and Safety of Bevifibatide Citrate Injection in Patients With Acute Ischemic Stroke Without Large or Medium-Sized Vessel Occlusion: A Single-Center, Randomized, Double-Blind, Dose-Response Controlled Clinical Trial","BCAIS-I","Inclusion Criteria:\n\n* Any of the following presentations of acute ischemic stroke (AIS): ① Within 24 hours of time last known well and ineligible for intravenous thrombolysis (IVT) or endovascular treatment (EVT). ② More than 24 hours and less than 96 hours after time last known well but within 24 hours of ischemic stroke progression \\[worsening of ≥ 2 points on the NIHSS\\]; and ineligible for IVT or EVT without ICH confirmed by CT scan or MRI. ③ Treated with IVT followed by early neurological deterioration (worse NIHSS by ≥ 4 points) within the first 24 hours after IVT without ICH confirmed by CT scan or MRI. ④ Treated with IVT followed by no neurological improvement (Neurological improvement is defined as decrease in the NIHSS score by ≥ 2 points) from baseline within 4 to 24 hours after IVT without ICH confirmed by CT scan or MRI.\n* NIHSS score ≥ 3 immediately prior to trial entry.\n* Without visible large or medium intracranial vessel occlusion on CT angiography (CTA), MR angiography (MRA), or digital subtraction angiography (DSA). (Qualifying mechanisms are: 1. hypoperfusion caused by arterial stenosis; 2. the initial occluded large or medium artery spontaneously recanalized or recanalized with IVT before the vascular imaging performed; 3. multiple or single distal emboli from cardiac or other sources in arterial branches too small to visualized on CTA or MRA; 4. lacunar infarct due to small vessel occlusion).\n* Written informed consent obtained from patients or their legal representatives.\n\nExclusion Criteria:\n\n* CT or MR evidence of intracranial haemorrhage.\n* Pre-morbid disability with a mRS score ≥ 2.\n* Presence of any of the following unequivocal cardiac sources of embolism: chronic or paroxysmal atrial fibrillation, sick sinus syndrome, mitral stenosis, mechanical valve, endocarditis, intracardiac clot or vegetation, myocardial infarction within three months, dilated cardiomyopathy, left atrial spontaneous echo contrast, ejection fraction less than 30%.\n* Planned treatment with dual antiplatelet therapy within 1week of the index stroke.\n* Any history of a primary or other intracerebral (parenchymal) haemorrhage (intraventricular, subarachnoid, subdural, epidural).\n* Any untreated or incompletely treated intracranial aneurysm, any intracranial vascular malformation or any intracranial tumour.\n* Currently pregnant or lactating, and those planned to conceive.\n* Subjects with positive urine HCG test results.\n* Known allergy to study medication or concomitant medications.\n* Gastrointestinal bleeding, urinary tract bleeding, or other major systemic haemorrhage within 30 days.\n* Any major surgery within 6 weeks of the index stroke.\n* History of heparin-induced thrombocytopenia.\n* Expected lifespan less than 3 months.\n* Pre-existing neurological or psychiatric disease that would confound the neurological functional outcome evaluations.\n* Any of the following laboratory tests: INR \\[International Normalized Ratio\\]\\>2.0, PT\\>1.3 times normal value, platelet count\\\u003C100 × 109\u002FL, Hb\\\u003C10g\u002Fdl.\n* Systolic pressure greater than 180 mmHg or diastolic pressure greater than 110 mmHg after aggressive treatment.\n* Severe renal insufficiency (glomerular filtration rate \\\u003C 30 ml\u002Fmin or serum creatinine \\> 220 μmol\u002FL \\[2.5 mg\u002Fdl\\]).\n* History of liver dysfunction (AST\u002FALT exceeding the upper limit of normal by more than twice) or cirrhosis.\n* Arterial tortuosity and\u002For other arterial diseases that prevent the expected internal thrombectomy device from reaching the target vessel.\n* Unlikely to be available for 90-day follow-up.\n* Current participation in another treatment clinical trial.\n* Other conditions that are not suitable for participation in the study.",{"count":490,"type":23},[116],"BCAIS-I is a single-center, randomized, double-blind, dose-response controlled clinical Trial, to preliminarily explore the efficacy of two different maintenance doses of bevifibatide citrate injection in improving 90-day neurological outcomes and the incidence of symptomatic intracranial hemorrhage in patients with acute ischemic stroke without large or medium-sized vessel occlusion, aiming to identify a dosing regimen that maintains therapeutic efficacy while minimizing the rates of symptomatic intracranial hemorrhage and serious adverse events, thereby providing dosing evidence for future large-scale randomized controlled trials.",[30,62,571,572],"Cerebral Infarction","Brain Diseases",[574,575,376],"Bevifibatide citrate injection","Dose-response controlled","2025-07-15",{"date":578,"type":39},"2025-07-17",{"date":580,"type":39},"2025-02-10",{"date":323,"type":23},{"name":583,"class":46},"Zhujiang Hospital",{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":4,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":591,"targetDuration":4,"studyType":24,"phases":593,"briefSummary":594,"conditions":595,"keywords":598,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":603,"lastUpdatePostDateStruct":604,"startDateStruct":606,"completionDateStruct":608,"leadSponsor":610,"locationsCount":47},"100596302","cerebrolysin-in-early-stroke-rehabilitation---tertiary-study-100596302","NCT07043686","Cerebrolysin in Early Stroke Rehabilitation - Tertiary Study","Effect of Cerebrolysin on Early Rehabilitation After Ischemic Stroke at the Department of Vascular Neurology and Intensive Neurological Therapy (KOVNINT), University Medical Centre Ljubljana","Inclusion Criteria:\n\nBeing able to perform ARAT test Signed informed consent\n\nBoth sexes, age not specified\n\nAcute ischemic stroke confirmed by imaging\n\nNIHSS score 6-12\n\nNo prior stroke or disability (mRS 0 before stroke)\n\n\\-\n\nExclusion Criteria:\n\nNot being able to perform ARAT test\n\n* Previous stroke or disability (mRS \\> 0)\n* The patient unable to understand instructions",{"count":592,"type":23},30,[86],"The study evaluates the effect and safety of Cerebrolysin administered during early rehabilitation in patients with moderate neurological impairment after acute ischemic stroke, conducted at the Department of Vascular Neurology and Intensive Neurological Therapy, UMC Ljubljana.",[30,596,597],"Rehabilitation Outcome","Cerebrolysin",[597,376,599,600,601,602],"Neuroplasticity","Neurorehabilitation","Action Research Arm Test","Slovenia","2025-07-03",{"date":605,"type":39},"2025-07-09",{"date":607,"type":39},"2025-06-13",{"date":609,"type":23},"2027-10-15",{"name":611,"class":46},"University Medical Centre Ljubljana",{"id":613,"slug":614,"hasResults":12,"nctId":615,"briefTitle":616,"officialTitle":617,"acronym":4,"eligibilityCriteria":618,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":619,"targetDuration":620,"studyType":316,"phases":4,"briefSummary":621,"conditions":622,"keywords":623,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":47},"100586816","accuracy-of-transcranial-colour-coded-duplex-in-comparing-with-ct-angiography-100586816","NCT06920303","Accuracy of Transcranial Colour Coded Duplex in Comparing With CT Angiography","Accuracy of Transcranial Colour Coded Duplex Compared With CT Angiography in Diagnosing Arterial Obstructions in Acute Ischemic Strokes","Inclusion Criteria:\n\n* patients who have acute ischemic strokes or transient ischemic attacks .\n\nExclusion Criteria:\n\n1. Patients with history of cardiac arrhythmia or discovered recently or known rheumatic heart disease.\n2. Patients with history of autoimmune diseases.\n3. Patients with space occupying lesion or hemorrhage in Ct brain.\n4. Pregnant female.\n5. Patients who refuse to participate in the study.\n6. Patients who have history of allergy or developed acute kidney injury during previous dye injection.\n7. Patients who have chronic kidney disease.\n8. Premorbid neurological disorder (myopathy, multiple sclerosis) on neurological examination or previous investigations.\n9. Inability to achieve safe vascular access.\n10. Patients with insufficient temporal acoustic window.",{"count":417,"type":23},"3 Days","Investigator will compare accuracy of transcranial colour coded duplex with CT angiography in detecting arterial obstructions in patients presenting or with history of cerebrovascular ischemic strokes",[30],[624,625],"transcranial colour coded duplex","ct angiography","2025-05-12",{"date":628,"type":39},"2025-05-13",{"date":630,"type":39},"2025-05-01",{"date":632,"type":23},"2026-09-01",{"name":634,"class":46},"Sohag University",{"id":636,"slug":637,"hasResults":12,"nctId":638,"briefTitle":639,"officialTitle":640,"acronym":641,"eligibilityCriteria":642,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":643,"targetDuration":4,"studyType":24,"phases":645,"briefSummary":646,"conditions":647,"keywords":648,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":650,"lastUpdatePostDateStruct":651,"startDateStruct":653,"completionDateStruct":655,"leadSponsor":657,"locationsCount":74},"100454601","phase-3-randomization-to-extend-stroke-intravenous-thrombolysis-in-evolving-non-large-vessel-occlusion-with-tnk-resilient-100454601","NCT05199662","Randomization to Extend Stroke Intravenous ThromboLysis In Evolving Non-Large Vessel Occlusion With TNK (RESILIENT","A Phase III, Randomized, Multi-center Clinical Trial That Will Examine Whether Treatment With Intravenous TNK is Superior to Placebo in Patients Who Suffer a Non-large Vessel Occlusion Ischemic Stroke Within 4.5-12 Hours From Time Last Seen Well","EXTEND-IV","Inclusion Criteria:\n\n1. Acute ischemic stroke where patient is ineligible for IV thrombolytic treatment with Alteplase due to onset \\>4.5 hours and is ineligible for endovascular treatment under standard of care due to absence of proximal arterial occlusion (e.g. intracranial ICA, MCA-M1 and dominant M2 segments, and vertebrobasilar arteries).\n\n   \\* Dominant M2 segment is defined is a division supplying \\>50% of the MCA territory vs co-dominant supplying 50% of the MCA territory vs non-dominant supplying \\\u003C50% of the MCA territory.\n2. No significant pre-stroke functional disability (mRS ≤2).\n3. Age ≥18 years (no upper age limit).\n4. Clinical or imaging mismatch evidence in distal artery territories, defined as one of the following scenarios (A, B or C):\n\n   * Scenario A - all of the following:\n\n     * Significant cortical neurological deficit (moderate to severe afasia, moderate to severe heminegligence, severe hemianopsia) with the addition or not of motor symptoms OR any motor deficit accompanied of cortical symptoms of any severity;\n     * Contrast-enhanced CT of the head or head MRI with \\\u003C50% involvement of the vascular territory corresponding to the clinical manifestation;\n     * Arterial head angiotomography or arterial head angioMRI WITHOUT proximal intracranial artery occlusion that would require endovascular therapy (for example, ICA intracranial, MCA-M1 and M2 dominant segments and vertebral and basilar arteries)\n   * Scenario B - all of the following:\n\n     * NIHSS score ≥ 4 due to any neurologic deficits;\n     * Non-contrast CT of the head or head MRI com \\\u003C50% involvement of the vascular territory corresponding to the clinical manifestation;\n     * Arterial head angioCT or arterial head MRI WITHOUT proximal intracranial artery occlusion that would require endovascular therapy (for example, ICA intracranial, MCA-M1 and M2 dominant segments and vertebral and basilar arteries)\n     * Arterial head angioCT with distal occlusion on MIP or wedge-shaped lesion on parenchymography on the source-image of angiotomography OR CT perfusion with wedge-shaped cortical lesion.\n   * Scenario C - all of the following:\n\n     * NIHSS score ≥ 4 due to any neurologic deficits;\n     * The presence of a Target Mismatch defined as:\n\n       * Ischemic Core \\\u003C50cc (defined on NCCT\u002FCTP\\* or DWI MRI) \\*Volume NCCT can be used to exclude patients if the investigator believes that its volume assessment is more reliable that the CTP in any particular case.\n       * Mismatch Volume (Tmax \\>6sec lesion - Core volume lesion) \\>10cc\n       * Mismatch Ratio \\>1.4\n5. Patient treatable within 4.5-12 hours of symptom onset. Symptoms onset is defined as point in time the patient was last seen well (at baseline). Treatment start is defined as initiation of IV TNK or placebo infusion.\n\n   * Patients who have woken up with the symptoms and don't have a mismatch FLAIR-DWI according to the WAKE-UP Trial image criteria will have their window considered to be \\>4.5 hours. In this case, the time last seen well must have been 12 hours at most.\n6. Informed consent obtained from patient or acceptable patient surrogate.\n\nExclusion Criteria:\n\n1. Intracranial hemorrhage (ICH) identified by CT or MRI.\n2. Rapidly improving symptoms, particularly if in the judgment of the managing clinician that the improvement is likely to result in the patient without eligibility criteria.\n3. Pre-stroke mRS score of ≥ 2 (indicating previous disability)\n4. Contra indication to imaging with MR or CT with contrast agents.\n5. Infarct core \\>1\u002F3 MCA territory qualitatively or \\>50 mL quantitatively (determined by DWI lesion on MR).\n6. Participation in any investigational study in the previous 30 days\n7. Any terminal illness such that patient would not be expected to survive more than 1 year).\n8. Baseline platelet count \\\u003C 100.000\u002FµL\n9. Woman of childbearing potential who is known to be pregnant or who has a positive pregnancy test on admission.\n10. Previous stroke within last three months.\n11. Recent past history or clinical presentation of ICH, subarachnoid hemorrhage (SAH), arterio-venous (AV) malformation, aneurysm, or cerebral neoplasm other than meningioma.\n12. Current use of oral anticoagulants and a prolonged prothrombin time (INR \\> 1.6).\n13. Use of heparin, except for low dose subcutaneous heparin, in the previous 48 hours and a prolonged partial thromboplastin time exceeding the upper limit of the local laboratory normal range\n14. Use of glycoprotein IIb - IIIa inhibitors within the past 72 hours. Use of single agent oral platelet inhibitors (clopidogrel or low-dose aspirin) prior to study entry is permitted.\n15. Clinically significant hypoglycemia.\n16. Uncontrolled hypertension defined by a blood pressure \\> 185 mmHg systolic or \\>110 mmHg diastolic on at least 2 separate occasions at least 10 minutes apart, or requiring aggressive treatment to reduce the blood pressure to within these limits. The definition of \"aggressive treatment\" is left to the discretion of the responsible Investigator.\n17. Hereditary or acquired hemorrhagic diathesis.\n18. Gastrointestinal or urinary bleeding within the preceding 21 days.\n19. Major surgery within the preceding 14 days which poses risk in the opinion of the Investigator.\n20. Exposure to a thrombolytic agent within the previous 72 hours.\n21. Subject participating in a study involving an investigational drug or device that would impact this study.",{"count":644,"type":23},466,[26],"A phase III, randomized, multi-center clinical trial that will examine whether treatment with intravenous TNK is superior to placebo in patients who suffer a non-large vessel occlusion ischemic stroke within 4.5-12 hours from time last seen well. The randomization employs a 1:1 ratio of intravenous thrombolysis with Tenecteplase (TNK) versus placebo in patients who suffer a non-large vessel occlusion ischemic stroke between 4.5 and 12 hours from time last seen well (TLSW) and with a clinical-radiological mismatch or evidence of salvageable brain tissue on perfusion imaging.",[30],[62,649,123],"Thrombolysis","2025-04-02",{"date":652,"type":39},"2025-04-04",{"date":654,"type":39},"2022-01-20",{"date":656,"type":23},"2027-07",{"name":658,"class":46},"Hospital Moinhos de Vento"]